Introduction {#sec1-1}
============

Tuberculosis is one of the major causes of mortality worldwide and the leading cause of death.\[[@ref1]\] In WHO 2017 report, 3.5% of new cases and 18% of previously treated cases are estimated to be multidrug-resistant tuberculosis.\[[@ref2]\] The treatment of MDR-TB is complex and requires a long duration of therapy and toxic drugs.\[[@ref3][@ref4]\] Moreover, facility to diagnose MDR-TB is not readily available in low- and middle-income countries.\[[@ref5]\] The success rate of MDR-TB treatment is much lower compared to drug sensitive TB. Only 54% patients with MDR-TB completed treatment and death rate was 16% according to the WHO report.\[[@ref2]\] Some patients with MDR-TB may survive for many months, and therefore, the transmission and spread of infection from such patients is a major limiting factor for End TB strategies.\[[@ref6]\]

India accounts for the highest number of TB cases in the world and about one-fourth of global TB burden.\[[@ref6]\] A total of approximately one hundred and thirty thousand incident multidrug resistant patients with TB emerge annually in India which includes approximately 79,000 patients with MDR-TB among notified pulmonary cases.\[[@ref6]\] First National Drug Resistance Survey results showed the rates of MDR among new patients with TB to be 2.84% and that in previously treated patients to be 11.60%.\[[@ref7]\] In 2002, the Global Fund to Fight AIDS, TB and Malaria (GFATM) started financing TB programs, including DR-TB, thus greatly reducing the economic barrier to India for DR-TB.\[[@ref8]\] Detection and treatment of MDR-TB is a priority in National Tuberculosis program in India. Detection of DR-TB through Revised National Tuberculosis Control Program (RNTCP) has been progressively rising with increased access to various forms of drug-sensitivity testing (DST).\[[@ref9]\] In 2016, detection and treatment of MDR-TB has been started by RNTCP in more than 30,000 patients. However, completion of treatment and cure from MDR-TB still remain a challenge in India.\[[@ref10]\]

To date, the rate of MDR-TB has been reported in various report and surveys from India.\[[@ref11][@ref12]\] However, it is likely that surveys undertaken in India might underestimate the true burden of MDR-TB in India. The surveys conducted in India are mostly on smear positive TB thereby excluding smear negative and extra-pulmonary TB. Patients residing in jail and prisons were also not included in survey. Moreover, private sector contributes significantly to TB treatment but has been excluded from survey. These surveys are also limited to few metro cities. A comprehensive analysis of MDR-TB from different parts of India has not yet been performed. In addition, a reliable assessment of MDR-TB burden is needed for programmatic management in context of National tuberculosis program of India. The present systematic review and meta-analysis was designed to determine the prevalence of drug-resistant TB in adult patients in India. Results generated through this systematic review may add to the findings of the nationwide surveys regarding the prevalence of MDR-TB in India.

Materials and Methods {#sec1-2}
=====================

Search strategies {#sec2-1}
-----------------

PubMed and Google scholar were used to find studies related to the prevalence of MDR-TB in adult patients in India. Search was restricted to the original articles published in English language. Besides references mentioned in the review articles, previously published systematic reviews and meta-analysis etc., were also explored to find any new study which may fulfill the inclusion criteria. Keywords like "tuberculosis, multidrug-resistant", "tuberculosis", "MDR-TB", "MDR Tuberculosis", "Drug Resistance", "Prevalence", "India" etc., were used in Medical Subject Headings (MeSH), titles and abstracts with the help of Boolean operators in PubMed.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Observational studies which includes cross-sectional, cohort and retrospective chart reviews were included in the analysis. Studies which mention MDR-TB prevalence in new and/or previously treated patient with tuberculosis and where standard method of Drug Sensitivity Testing was used for the diagnosis were considered for the review. Review articles, meta-analyses and duplicates were removed from the analysis. Studies, which were conducted by same authors in two different timelines and included different patients, were analyzed as different studies.

Data extraction {#sec2-3}
---------------

Different data related to the studies and not restricted to the authors, year of publication, study setting, patient sample, prevalence of various types of drug resistances were included in the analysis. Data were extracted by two investigators independently and in the case of any discrepancy the third investigator was consulted to resolve the discrepancy. Data related to MDR-TB only was pooled for the analysis. Standard definitions for new cases, old cases and MDR-TB were used for characterization.

Statistical analysis {#sec2-4}
--------------------

Statistical analysis was done by using STATA software. Data were represented as pooled proportion with 95% CI. Random effect model was used for the analysis considering the chance of heterogeneity. A separate analysis was done for new cases as well as previously treated cases. For each of new and old cases separate analysis was done for the method of DST, sample size less or more than 500, proportion after removal of largest study and prospective or retrospective nature of the studies. Heterogeneity was assessed by I^2^ and Cochran Q test.

Results {#sec1-3}
=======

A total 86 original articles were included for the screening. After going through the abstracts, 36 studies were excluded and remaining 50 articles were selected for full text reading. Out of these 50 studies, 47 were selected for the analysis \[[Table 1](#T1){ref-type="table"}\]. Among the excluded studies, two were review articles/meta-analysis and one study was related to the specific tribal population \[[Flow chart 1](#F1){ref-type="fig"}\]. In almost all studies, data related to new cases as well as previously treated cases were extractable.

###### 

Various studies included in the analysis for systematic review and meta-analysis

  No   First author            Published time   Enrollment time       Province
  ---- ----------------------- ---------------- --------------------- ------------------------------------
  1    Dasarathi Das           2016             Jan 2014-Sep 2014     Bhubaneshwar, Odisha
  2    A. Jain                 2016             Oct 2012-Mar 2015     Uttar Pradesh
  3    R.Kumar                 2016             Aug 2014-Apr 2015     Lucknow district of Uttar Pradesh
  4    Vithal Prasad Myneedu   2015             July 2011-June 2012   Lala Ram Syrup district, New Delhi
  5    Parshuram Raao          2015             Sep 2011-Aug 2014     Udupi district, Karnataka
  6    N. Selvakumar           2015             May 2011-Aug 2012     Tamilnadu
  7    R.Singhal               2015             Oct 2011-Dec 2012     Delhi
  8    Sunita Tripathy         2015             Feb 2014-July 2014    Bihar
  9    D.Das                   2014             Feb 2012-Apr 2013     Rayagada district, Odisha
  10   Harshita Gupta          2013             Jan 2010-Mar 2011     Lucknow district of Uttar Pradesh
  11   Subhakar Kandi          2013             Dec 2010-Mar 2011     Hyderabad
  12   Chhavi Porwal           2013             Apr 2007-May 2010     Delhi
  13   Sunil Sethi             2013             Oct 2006-Feb 2010     Chandigarh
  14   R. Yadav                2013             2008-2010             Chandigarh
  15   Rajendra Prasad         2012             Aug 2003-July 2008    Uttar Pradesh
  16   Surendra Sharma         2011             Feb 2008-Dec 2009     New Delhi
  17   Surendra Sharma         2011             Mar 2005-Mar 2008     New Delhi
  18   C. Paramasivan          2010             2001-2004             Across India
  19   Desiree TB D'souza      2009             Apr 2004-Jan 2007     Mumbai
  20   M.Hanif                 2009             2006                  New Delhi
  21   B. Joseph               2009             1998-2005             Kerala
  22   S.Rajasekaran           2009             2004-2007             Chennai
  23   R. Ramachandran         2009             Nov 2005-Oct 2006     Gujarat
  24   Jagdish Rawat           2009             Jan 2002-Dec 2006     Dehradun, Uttarakhand
  25   R.Singla                2009             June 2006-Feb 2008    South Delhi
  26   Amita Jain              2008             Nov 2000-Oct 2002     Lucknow district of Uttar Pradesh
  27   M. Joseph               2007             May 2004-Sep 2004     Ernakulam district, Kerala
  28   B. Anuradha             2006             Jan 2001-Dec 2003     Hyderabad
  29   B.Mahadev               2005             Aug 2000-July 2001    Hoogli district, West Bengal
  30   B.Mahadev               2005             Aug 2000-May 2001     Mayurbhanj district, Orissa
  31   Mycal Pereira           2005             Sep 2000-July 2004    Pune
  32   Sophia Vijay            2004             Apr 1999-Dec 1999     Banglore, Karnataka
  33   D.Barat                 2003             Sep 1998-Sep 2000     Patna, Bihar
  34   C. Deivanayagam         2002             Oct 1997-May 2000     Chennai
  35   C. Paramasivan          2002             Feb 1999-Apr 1999     North Arcot district, Tamilnadu
  36   C. Paramasivan          2002             July 1999-Dec 1999    Raichur district, Karnataka
  37   A.Shah                  2002             Jan 2000-Aug 2001     Gujarat
  38   C. Paramasivan          2000             Feb 1997-Mar 1997     Tamilnadu
  39   P.Gopi                  1997             Nov 1988-Mar 1989     Raichur district, Karnataka
  40   R. Vasanthakumari       1997             NM                    Tamilnadu
  41   Manjula Dutta           1993             Apr 1986-Mar 1988     North Arcot district, Tamilnadu
  42   C. Paramasivan          1993             May 1985-Apr 1989     North Arcot district, Tamilnadu
  43   C. Paramasivan          1993             July 1985-June 1991   Pondicherry district
  44   Sujata Chanrasekaran    1992             1985-86               Banglore (urban), Karnataka
  45   Sujata Chanrasekaran    1992             1987-89               Kolar district (rural), Karnataka
  46   Sujata Chanrasekaran    1990             NM                    Banglore, Karnataka
  47   Sunil Trivedi           1988             Jan 1983-Dec 1986     Amargadh, Gujarat

NM=Not mentioned

![PRISMA Flow chart for inclusion of studies](JFMPC-8-3191-g001){#F1}

MDR-TB in new cases {#sec2-5}
-------------------

Thirty studies enrolled 16,275 participants and reported on new cases of MDR-TB. A pooled analyses of 30 studies (16,275 participants) showed 3% new cases of MDR-TB (95% CI 2%-5%). The heterogeneity between pooled studies was high (I^2^ = 95.3%) \[[Figure 1](#F2){ref-type="fig"}\].

![Prevalence of MDR-TB in new cases](JFMPC-8-3191-g002){#F2}

Among studies which used the proportion method, the pooled proportion of MDR-TB cases was 3% (95% CI 2%-4%) and heterogeneity between pooled studies was high (I^2^ = 88.0%). Among studies using the BACTEC method, the pooled proportion of MDR-TB cases is 21% (95% CI 18%-24%) and the heterogeneity between pooled studies was high (I^2^ = 99.3%). The single study which used the Alamar blue dye reduction assay reported 5% (95% CI 2%-12%) proportion of MDR-TB cases. Among studies using the MIC method, the pooled proportion of MDR-TB cases was 1% (95% CI 1%-2%) and the heterogeneity between studies was high (I^2^ = 85.9%). Finally, among studies where the method used was not reported, the pooled proportion of MDR-TB cases was 9% (95% CI 7%-11%) and the heterogeneity between studies was high (I^2^ = 98.0%). There was a statistically significant difference between the subgroups (*p* \< 0.001) \[[Figure 2](#F3){ref-type="fig"}\].

![Prevalence of MDR-TB as per method of measurement](JFMPC-8-3191-g003){#F3}

Among studies with less than 500 participants, the pooled proportion of MDR-TB cases was 4% (95% CI 2%-6%) while in the studies with more than 500 participants enrolled, the pooled proportion of MDR-TB cases was 2% (95% CI 1%-4%). The heterogeneity between studies was high for both groups, I^2^ = 94.0% and 96.2%, respectively. There was no statistically significant difference between the two groups (*p* = 0.117) \[[Figure 3](#F4){ref-type="fig"}\].

![Prevalence of MDR-TB in new cases in sample size of the study \<500 versus \>500](JFMPC-8-3191-g004){#F4}

The proportion of MDR-TB cases in the largest included study was 2% (95% CI 1%-2%). Without the largest study, the pooled proportion of MDR-TB cases was 3% (95% CI = 2%-5%) and heterogeneity between studies was high (I^2^ = 95.4%). There was a statistically significant difference between the largest included study and the remaining studies (*p* \< 0.001) \[[Figure 4](#F5){ref-type="fig"}\].

![Prevalence of MDR-TB when largest study excluded vs included](JFMPC-8-3191-g005){#F5}

A sensitivity analysis performed according to the timing of the studies shows that in prospective studies, the pooled proportion of MDR-TB cases was 3% (95% CI 2%-5%) while in retrospective studies the pooled proportion of MDR-TB cases was 4% (95% CI 0%-13%). In both subgroups, the heterogeneity between studies was high: I^2^ = 95.5% and 97.4%, respectively. Meanwhile, in studies where the timing of the study could not be evaluated the pooled proportion of MDR-TB cases was 3% (95% CI 2%-4%) and there was no heterogeneity between these studies (I^2^ = 0%). There was no significant difference between subgroups (*p* = 0.933) \[[Figure 5](#F6){ref-type="fig"}\].

![Prevalence of MDR-TB as per the study designs](JFMPC-8-3191-g006){#F6}

MDR-TB in previously treated cases {#sec2-6}
----------------------------------

Thirty two studies which enrolled 21,095 participants reported on previously treated cases of MDR-TB. A pooled analyses of 32 studies (21,095 participants) showed 35% cases of MDR-TB among the previously treated population (95% CI 29%-41%). There was significant heterogeneity between pooled studies (I^2^ = 98.7%) \[[Figure 6](#F7){ref-type="fig"}\].

![Prevalence of MDR-TB in previously treated cases](JFMPC-8-3191-g007){#F7}

Among studies which used the proportion method, the pooled proportion of MDR-TB cases was 28% (95% CI 20%-37%) and heterogeneity between studies was high (I^2^ = 95.2%). Among studies using the BACTEC method, the pooled proportion of MDR-TB cases was 58% (95% CI 31%-83%) and the heterogeneity between pooled studies was high (I^2^ = 99.4%). Among studies using the genotype MTB DR plus assay method, the pooled proportion of MDR-TB cases was 19% (95% CI 17%-20%) and the heterogeneity between pooled studies was high (I^2^ = 99.8%). The single study which used the RNTCP guideline reported proportion of MDR-TB cases at 28% (95%CI 19%-38%). Among studies using the absolute concentration method, the pooled proportion of MDR-TB cases was 53% (95% CI 51%-55%) and the heterogeneity between pooled studies was high (I^2^ = 99.8%). Among studies using the resistance ratio method, the pooled proportion of MDR-TB cases was 48% (95% CI, 47%-50%) and the heterogeneity between studies was high (I^2^ = 99.8%). The single study which used the Alamar blue dye reduction assay reported proportion of MDR-TB cases at 16% (95% CI 10%-25%). Among studies using the MIC method, the pooled proportion of MDR-TB cases was 26% (95% CI 12%-44%) and the heterogeneity between studies was high (I^2^ = 98.4%). The single study, which did not report a method but used L-J medium, reported proportion of MDR-TB cases at 57% (95% CI, 50%-65%). The single study which used the Lowenstein Jensen method reported proportion of MDR-TB cases at 72% (95% CI 58%-84%). The single study which did not report the method used had 17% (95% CI 11%-25%) cases of MDR-TB. The single study which used the standard procedure reported proportion of MDR-TB cases at 20% (95% CI 14%-27%). There was a statistically significant difference between the subgroups (*p* \< 0.001) \[[Figure 7](#F8){ref-type="fig"}\].

![Prevalence of MDR-TB in previously treated patients as per the methods of measurement](JFMPC-8-3191-g008){#F8}

Among studies with less than 500 participants, the pooled proportion of MDR-TB cases was 33% (95% CI 25%-42%) while in the studies with more than 500 participants enrolled, the pooled proportion of MDR-TB cases was 39% (95% CI 29%-50%). The heterogeneity between studies was high for both groups, I^2^ = 95.1% and 99.5%, respectively. There was no statistically significant difference between the two groups (*p* = 0.417) \[[Figure 8](#F9){ref-type="fig"}\].

![Prevalence of MDR-TB in previously treated patients when sample size is \<500 versus \>500](JFMPC-8-3191-g009){#F9}

The proportion of MDR-TB cases in the largest included study was 35% (95% CI 33%-36%). Without the largest study, the pooled proportion of MDR-TB cases was 35% (95% CI 28%-42%) and the heterogeneity among pooled studies is high (I^2^ = 98.7%). There was a statistically significant difference between the largest included study and the remaining studies (*p* \< 0.001) \[[Figure 9](#F10){ref-type="fig"}\].

![Prevalence of MDR-TB in previously treated patients when largest study excluded versus included in the analysis](JFMPC-8-3191-g010){#F10}

A sensitivity analysis performed by the timing of the studies showed that in prospective studies, the pooled proportion of MDR-TB cases was 33% (95% CI, 25%-43%) while in retrospective studies the pooled proportion of MDR-TB cases was 31% (95% CI, 22%-41%). In both groupings the heterogeneity between pooled studies was high, I^2^ = 98.7% and 99.0%, respectively. Meanwhile, in studies where the timing of the study could not be evaluated the pooled proportion of MDR-TB cases was 69% (95% CI 20%-100%) and the heterogeneity between studies was high (I^2^ = 90.6%). There was no significant difference between the three subgroups (*p* = 0.317) \[[Figure 10](#F11){ref-type="fig"}\].

![Prevalence of MDR-TB in previously treated patients as per the study designs](JFMPC-8-3191-g011){#F11}

Discussion {#sec1-4}
==========

The current analysis showed a prevalence of 3% and 28% MDR-TB in new and previously treated TB cases, respectively. The prevalence of MDR-TB in new cases was similar to the survey conducted at the National level. The national survey reported prevalence of MDR-TB in new cases as 2.8%. The prevalence of MDR-TB in previously treated patients is found to be higher in the current study compared to the National level survey. Current study found the prevalence to be 35% as compared with 11.6% estimated by the National level survey.\[[@ref13]\] The of prevalence in any National program is based on sample presented to government health facility for drug sensitivity testing in MDR-TB suspects which might not be true representative of real situation.\[[@ref14][@ref15]\]

A study by Goyal *et al.* (2017) estimated the prevalence of MDR-TB 1%-2% higher in new cases as compared to our study while prevalence of MDR-TB in previously treated cases is almost similar to our study.\[[@ref16]\] Such kind of systematic reviews always have the component of heterogeneity looking at the different kinds of studies pooled together but sensitivity analysis/subgroup analysis shows that estimates for each subgroups falls within the CIs of primary estimate. So even if we consider lower end of CI for MDR-TB in new and previously treated patients that is 2% and 29%, respectively, the values of previously treated patients is higher than national survey.

The low rate of MDR-TB in new patients and the high rate in previously treated patients indicates that most of the newly diagnosed TB patients are sensitive to first line drugs but there is an issue with the process of treatment which induces secondary resistance. This may be either due to inappropriate dosing, duration and variability in prescription of anti-tubercular drugs by clinicians particularly from private sector.\[[@ref17][@ref18]\] Moreover, intermittent therapy under Directly Observed Treatment Short Course (DOTS) strategy may also lead to increase in resistance which has now been shifted to daily therapy under new RNTCP guidelines.\[[@ref19]\] In India, one of the important factor for the development of MDR-TB is the rampant use of antibiotics due to over the counter availability with no regulatory mechanism for the pharmacy shops.

This review is not devoid of potential limitations. Looking at the chances of heterogeneity in such studies, the random model was used for the analysis but mere using this model does not remove every influence of heterogeneity on estimates. There may be many confounders which could be adjusted to remove heterogeneity but not possible in aggregate data meta-analysis. The results obtained in this study as well in the national survey may be bit overestimated as compared to real situation as in both the cases MDR-TB was assessed in suspected drug resistant cases and not random or consecutive patients. A survey on patients of TB selected randomly without considering risk for resistance need to be planned to get true picture.

There are some very interesting observations from this review. Firstly, there is a lack of standard method for drug sensitivity testing (DST) across the country which government of India has also realized and started universal DST with WHO recommended rapid diagnostic testing. Secondly, a large part of care for TB patients is provided by private practitioners and patients are not followed under DOTS which may lead to inadequate and irregular treatment.\[[@ref20]\] To support TB notification and strengthen TB surveillance in general, a case-based, web-based TB notification system NIKSHAY was established to provide platform for notification from both public and private sector. By making TB notification mandatory by the treating doctor this problem might be resolved and in future more robust follow-up of patient with TB may happen. Since newer and effective drug like bedaquline, delamanid, etc., are made available under RNTCP program, MDR-TB now be treated more effectively.

To conclude, there is a growing prevalence of MDR-TB in India which may be an obstacle to End TB strategy adopted by WHO and government of India. The results from this review supports the priority need of having a continuous surveillance of MDR-TB. The role of primary care physician and primary health center (PHC) is of paramount importance. The staff at primary care should be trained with latest guideline on MDR-TB and made aware when to send sputum culture and DST for patients with TB, since patients' first encounter is with them. There should also be a link between PHC provider and TB services at district level. Good communication between PHC provider and TB services can be useful for detecting and treating patients with MDR-TB. It would also help the clinicians as well as public health experts to remain alert as well as vigilant for the timely response to MDR-TB cases occurring in an area. Future research in evidence-based diagnosis, management and prevention will help to eradicate TB.
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